Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines

Cancer Letters

Volumn 187, Issue 1-2, 2002, Pages 185-190

  Zajc, Irena ^a   Sever, Nataša ^a   Bervar, Aleš ^a   Lah, Tamara T ^a  

^a NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

Author keywords

Cathepsins; Invasiveness; Stefins; Tumorigenicity

Indexed keywords

CATHEPSIN L; MESSENGER RNA; STEFIN A; STEFIN B;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

BREAST NEOPLASMS; CATHEPSINS; COLLAGEN; CYSTATINS; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DISEASE PROGRESSION; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LAMININ; NEOPLASM INVASIVENESS; PROTEOGLYCANS; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 0037058622     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00452-4     Document Type: Article

References (22)

1. Lah T.T., Kos J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem. 379:1998;125-130.
2. Koblinski J.E., Ahram M., Sloane B.F. Unravelling the role of peptidases in cancer. Clin. Chem. Acta. 291:2000;113-135.
3. Lah T.T., Kokalj-Kunovar M., Štrukelj B., Pungerčar J., Barlič-Maganja D., Drobnič-Košorok M., Kastelic L., Babnik J., Golouh R., Turk V. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int. J. Cancer. 50:1992;36-44.
4. Lah T.T., Kos J., Blejec A., Frkovič-Grazio S., Golouh R., Vrhovec I., Turk V. The expresion of lysosomal proteinases and their inhibitors in breast cancer: possible relationship to prognosis of the disease. Pathology Oncology Res. 3:1997;221-233.
5. Thomssen C., Schmitt M., Goretzki L., Oppelt P., Pache L., Dettmar P., Janicke F., Graeff H. Prognostic value of the cysteine peptidase cathepsin B and cathepsin L in human breast cancer. Clin. Cancer Res. 1:1995;741-746.
6. Kos J., Lah T.T. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol. Rep. 5:1998;1349-1361.
7. Foekens J., Kos J., Peters H.A., Krašovec M., Look M.P., Cimerman N., Meijer-van-Gelder M., Henzen-Logmans S.C., Putten W.L.J., Kljin J.G.M. Prognostic significance of cathepsin B and L in primary human breast cancer. J. Clin. Oncol. 16:1998;1013-1021.
8. Lah T.T., Čerček M., Blejec A., Kos J., Gorodetsky E., Somers R., Daskal I. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L and other clinical indicators. Clin. Cancer Res. 6:2000;578-584.
9. R. Jerala, The effect of mutations of recombinant human stefins on their interaction with cysteine proteinases, University of Ljubljana (1993), Dissertation thesis.
10. Henskens Y.M.C., Veerman E.C.I., Amerongen A.V.N. Cystatins in health and disease. Biol. Chem. 377:1996;71-86.
11. Calkins C.C., Sloane B.F. Mammalian cysteine peptidase inhibitors: biochemical properties and possible roles in tumor progression. Biol. Chem. 376:1995;71-80.
12. Levičar N., Kos J., Blejec A., Golouh R., Vrhovec I., Frkovič-Grazio S., Lah T.T. Comparison of cysteine proteinases cathepsin B, cathepsin L and serine proteinase urokinase (u-PA) and their endogenous inhibitors with clinico-pathological data of breast carcinoma patients. Cancer Detect. Prev. 26:2002;42-49.
13. Xin H., Stephans J.C., Duan X., Harrowe G., Kim E., Grieshammer U., Kingsley C., Giese K. Identification of a novel aspartic-like peptidase differentially expressed in human breast cancer cell lines. Biochim. Biophys. Acta. 1501:2000;125-137.
14. Price J.E., Polyzos A., Zhang R.D., Daniels L.M. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 50:1990;717-721.
15. Albini A., Iwamoto Y., Kleinman H.K., Martin G.R., Aaronson S.A., Kozlowski J.M., McEwen R.N. A rapid in vitro assay for quantitation of the invasive potential of tumor cells. Cancer Res. 47:1987;3239-3245.
16. Thompson E.W., Paik S., Brunner N., Sommers C.L., Zugmaier G., Clarke R., Shima T.B., Torri J., Donahue S., Lippman M.E., Martin G.R., Dickson R.B. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J. Cell. Physiol. 150:1992;534-544.
17. Holst-Hansen C., Johannessen B., Hoyer-Hansen G., Romer J., Ellis V., Brunner N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin. Exp. Metastasis. 14:1996;279-307.
18. Evans D.M., Sloan-Stakleff K. Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428. Am. Surg. 66:2000;460-464.
19. Sloane B.F., Moin K., Lah T.T. Regulation of lysosomal endopeptidases in malignant neoplasia. Pretlow T.G., Pretlow T.P., Biochemical and Molecular Aspects of Selected Cancers. 1994;411-472 Academic Press, New York.
20. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
21. Schmitt M., Janicke F., Graeff F. Tumor-associated proteinases. Fibrinolysis. 6:1992;3-26.
22. Kuopio T., Kankaanranta A., Jalava P., Kronqvist P., Kotkansalo T., Weber E., Collan Y. Cysteine proteinase inhibitor cystatin A in breast cancer. Cancer Res. 58:1998;432-436.